The FDA on December 14, 2023, approved WELIREG® for patients with advanced Renal Cell Carcinoma (RCC) following a Programmed Death receptor-1 (PD-1) or Programmed Death-Ligand 1 (PD-L1) inhibitor and a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor (VEGF-TKI). WELIREG® is a product of Merck & Co., Inc.
Bottom Ad
Advertisement
Subscribe
